Omega eyes ‘significant progress’ as profits jump
The Alva-based firm, which specialises in test for allergies, food intolerances and infectious diseases, posted an adjusted pre-tax profit of £1.1 million for the year to 31 March, up from £780,000 a year earlier, on turnover 3 per cent higher at £11.6m.
Chairman David Evans the firm’s outlook was “brightened” by the prospects for its Visitect CD4 test, which is undergoing field trials among HIV patients in Africa and India.
He added: “We will make significant progress this year in terms of gaining market acceptance for CD4 and I believe the prospects for the group remain positive.”